Merck Makes use of Legal Threats To Stifle Negative Suggestions About Zetia And Vytorin In Italy

In response to repeated legal threats, a public health physician in Italy has withdrawn tips to curtail use of a controversial drug. The drug, ezetimibe, is a important ingredient in Zetia and Vytorin, which is produced by Merck Merck. The cholesterol-reducing drug has been the subject of fierce controversy due to the fact it has never ever been shown to improve clinical outcomes. Regardless of the controversy, in 2013 the medicines had mixed revenue of a lot more than $ two.six billion.

MSD Italy, the Italian arm of the company, sent two “cease and desist” letters to Alberto Donzelli, who is “the head of education, appropriateness, and evidence based mostly medication at the public health authority of Milan (Milan Healthcare),” according to The  BMJ, which published a information report of the affair. The letter was also sent to Milan Healthcare’s director standard and to Roberto Carlo Rossi, the president of the physicians’ regulatory organization in Milan.

As reported in The BMJ, right after the very first letter Rossi replied that the medical commission had concluded “that there was no purpose to object on ethical grounds to Donzelli’s behaviour. Donzelli also replied to every single level raised in the letter. ‘I exercised my right to inform the general practitioners what emerged from our in-depth analyses of the published literature, on a peer to peer basis.’”

In a second letter MSD Italy “reaffirmed its intention to go to court except if Donzelli stopped his ‘seriously damaging action, [that was] tarnishing the company’s and the drug’s picture and status.’” MSD’s medical director, Patrizia Nardini, advised The BMJ: “We are in favour of balanced info, and we decided to write individuals letters simply because we didn’t see a willingness to assess all the data in a balanced way.”

Last month Donzelli capitulated and removed the contentious material from his internet site “until the problem is more clarified within the scientific neighborhood,” The BMJ reports.

In a published statement, quoted by The BMJ, the editors of 5 Italian publications expressed assistance for Donzelli: “In the educational and informational process, the disagreement should be expressed on the pages of scientific journals as a debate between peers, such as the readers who will be ready to determine freely what is the most proper option for individuals.”

Donzelli is hardly alone in criticizing the continued use of ezetimibe in spite of the absence of evidence for clinical benefit. Just recently, ACP Internist, an inner medicine website, raised the query: “Why are we even now prescribing what appears to be a ineffective drug?” The continued use of ezetimibe in clinical practice was also the topic of a information feature in JAMA.

Merck Makes use of Legal Threats To Stifle Negative Suggestions About Zetia And Vytorin In Italy

Why Merck Just Invested $four Billion On New Drugs For Hepatitis C

Merck announced that it is buying Idenix of Cambridge, Mass., a maker of hepatitis C drugs, for $ 3.85 billion, or $ 24.50 a share, a 238% premium over Idenix’s closing price on Thursday.  The deal is expected to close in the third quarter.

With the deal, Merck is doubling down on the ability of its own hepatitis C drugs, all still experimental, to compete with those of Gilead, which has had the most successful drug launch ever with its $ 1,000 pill, Sovaldi, this year. Sovaldi generated sales of $ 2.3 billion during its first quarter on the market, and Gilead is expected to launch a three-drug combination pill in October. Sovaldi’s price and its rapid uptake in usage have resulted in worries among insurance companies and government officials that the drug is too expensive to afford.

In an interview, Roger Perlmutter, the president of Merck Research Laboratories, said that he believes that triple drug combinations are “the future ” in hepatitis C, and that he expects to be able to reduce the duration of treatment from two months for Gilead’s treatments to as little as a month. Owning all three types of drugs needed to cure people of the virus is the fastest way to move forward.  

Hepatitis C affects as many as 170 million people worldwide and can lead to liver failure. Many Wall Street investors seem to believe that Gilead will manage to hold on to this lucrative hepatitis C market indefinitely, with competitors like Merck and AbbVie, which is bringing another hepatitis C drug combo to market, taking what’s left behind. With today’s deal, Merck is betting they are wrong. “”Let’s recognize that there are on the order of 170 million people who have hepatitis C infection,” says Perlmutter. “You’re not going to treat a substantial fraction of the world’s infections in a few years. It’s just impossible.”

Among hepatitis C acquisitions, the Idenix deal still ranks behind Gilead’s $ 11 billion purchase of Pharmasset, which gave it Sovaldi, but ahead of Bristol-Myers Squibb’s purchase of Inhibitex for $ 2.5 billion. Bristol had to halt development on Inhibitex’s lead drug after nine patients were hospitalized and one died.

Worries about toxicity have also held Idenix back. After Bristol abandoned the Inhibitex compounds, the Food and Drug Administration told Idenix to stop clinical trials of its two lead drugs, both a type of hepatitis C drug called a nucleotide polymerase inhibitor. In February, Idenix abandoned those drugs, continuing instead with the two medicines that led to Merck’s purchase of the company.

Why Merck Just Invested $four Billion On New Drugs For Hepatitis C

FDA Approves Novel Merck Drug To Stop Heart Attacks And Strokes

The FDA nowadays approved vorapaxar (Zontivity), Merck’s Merck’s after-troubled platelet receptor antagonist, to minimize the danger of myocardial infarction (heart assault), stroke, cardiovascular death, and revascularization procedures. The drug is accepted for use in people with a background of MI or peripheral arterial illness. The approval represents an wonderful turnaround for a drug that had knowledgeable nearly as several ups and downs as an amusement park roller coaster.

Vorapaxar is the 1st in a new drug class recognized as protease-activated receptor-1 (PAR-one) antagonists. By stopping the capability of platelets to stick collectively and kind blood clots, the drug can support prevent MI and stroke. But it also increases the chance of bleeding, which includes daily life-threatening and fatal bleeding. Simply because the threat of significant intracranial bleeding is specially large in individuals who have had a stroke, a transient ischemic assault, or bleeding in the head, use of the drug is contraindicated in these groups. The drug’s label consists of a boxed warning about the chance of bleeding. The FDA stated the drug will be dispensed with a patient Medication Guidebook.

Vorapaxar appeared to be all but dead a number of years in the past following unacceptably substantial significant bleeding costs had been identified in two huge clinical trials. But hopes for the drug resurfaced with a new examination of one of these trials, the TRA2P trial. In a statement to the press, Ellis Unger, director of the FDA’s Workplace of Drug Evaluation I, mentioned that the trial showed that “in sufferers who have had a heart assault or who have peripheral arterial illness, this drug will lower the risk of heart assault, stroke, and cardiovascular death…  Zontivity lowered this danger from 9.five percent to seven.9 % over a three-yr period – about .5 percent per yr.”

In January the FDA’s Cardiovascular and Renal Medication Advisory Committee voted 10-one in favor of approval for vorapaxar.

FDA Approves Novel Merck Drug To Stop Heart Attacks And Strokes

Packaging Defect Leads Merck To Recall All Tons of Liptruzet In US

Merck Merck said right now that it was recalling all plenty of Liptruzet, its mixture of the cholesterol-reducing drugs ezetimibe and atorvastatin, in the US. The company said the recall was due to a packaging defect which could probably enable air and moisture to impact the high quality of the drug, however the company said “the probability of the packaging defects decreasing the effectiveness of Liptruzet on a patient’s lipid profile or negatively impacting the safety of the product is remote.” To date there have been no adverse occasions or item complaints reported to the organization.

Merck is recalling the drug from US wholesalers but is not asking patients or pharmacies to return their stock. The company stated that patients may continue taking the capsules currently in their possession.

Right now action will deplete the recent supply of the drug in the US, the organization said. The firm mentioned it will resupply the drug “as quickly as attainable.” Each substances of Liptruzet, atorvastatin and ezetibie, are offered in generic form from numerous makers.

Packaging Defect Leads Merck To Recall All Tons of Liptruzet In US